As of 2022, the small molecule targeting inhibitors approved by China Food and Drug Administration (CFDA) available for lung cancer treatment in China are epidermal growth factor receptor (EGFR) inhibitors including vascular endothelial growth factor (VEGFR) and anaplastic lymphoma kinase (ALK) inhibitors. Here, EGFR is linked to lung carcinoma.